

Patent Application  
Attorney Docket No. PC30520A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 10th day of May, 2005.

By

*Heather Randhahn*

(Signature of person mailing)  
Heather Randhahn

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Anders Berkenstam et al. :

APPLICATION NO.: 09/143,828 : Examiner: Michael D. Pak

FILING DATE: 08/31/1998 : Group Art Unit: 1646

TITLE: NR112 RECEPTOR RELATED :  
POLYPEPTIDES, NUCLEIC ACID  
SEQUENCES ENCODING THE SAME AND  
USES THEREOF (As Amended)

Hon. Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: May 10, 2005

Respectfully submitted,




Nicholas I. Slepchuk, Jr.  
Attorney for Applicant(s)  
Reg. No. 32,174

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(617) 551-3223

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>ATTY. DOCKET NO.</b> PC30520A				<b>SERIAL NO.</b> 09/143,828			
				<b>APPLICANT</b> Anders Berkenstam et al.							
				<b>FILING DATE</b> 08/31/1998				<b>GROUP</b> 1646			



U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
			6	3	9	1	8	4	7 B1	05/21/02	Evans et al.	514	2	
			6	8	0	9	1	7	8 B2	10/26/04	Evans et al.	530	350	

FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
			Blumberg, Bruce et al., "SXR, a novel steroid and xenobiotic-sensing nuclear receptor", <i>Genes &amp; Development</i> , 12:3195-3205, 1998.									
			Fukuen, Shuichi, et al., "Identification of the novel splicing variants for the hPXR in human livers", <i>Biochemical and Biophysical Research Communications</i> 298 (2002), 433-438.									
			Kliewer, Steven A., et al., "An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway", <i>Cell</i> , Vol. 92, 73-82, January 9, 1998.									
			Lehmann, Jürgen M. et al., "The Human Orphan Nuclear Receptor PXR is Activated by Compounds That Regulate CYP3A4 Gene Expression and Cause Drug Interactions", <i>J. Clin Invest.</i> , The American Society for Clinical Investigation, Inc., Volume 102, Number 5, September 1998, 1016-1023.									
			Nuclear Receptors Nomenclature Committee, "A Unified Nomenclature System for the Nuclear Receptor Superfamily", <i>Cell</i> , Vol 97, 161-163, April 16, 1999.									

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.